eligibility_summary
Eligible: adults with resected PDAC (R0/R1), AJCC 8th T1–3 N0–2 M0, tumor sample available, ECOG 0–1, life expectancy ≥6 months, post-op recovery (≤Clavien-Dindo grade 2), adequate organ/marrow, agree to contraception. Exclude: prior PDAC therapy, unsuitable for immunotherapy, recent live vaccine, active/treated autoimmune disease, TB, interstitial lung disease, severe allergy, malignancy <5y, prior transplant, splenectomy, recent severe infection, immunodeficiency, active HBV/HCV, uncontrolled CV disease, or investigator deems unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Early-phase, open-label trial in resected pancreatic adenocarcinoma testing: 1) Personalized neoantigen mRNA tumor vaccine (therapeutic mRNA vaccine) that delivers patient-specific neoantigen transcripts to antigen-presenting cells, driving MHC I/II presentation and priming CD8+ cytotoxic and CD4+ helper T-cell responses. 2) Adebrelimab, an anti–PD-L1 humanized monoclonal antibody (immune checkpoint inhibitor) that blocks PD-1/PD-L1 signaling to restore T-cell activity. Targets/pathways: dendritic cells, CD8+/CD4+ T cells, tumor/immune cell PD-L1, antigen presentation. Per title, given sequentially with mFOLFIRINOX (5-FU/leucovorin, oxaliplatin, irinotecan) targeting DNA synthesis/topoisomerase I in proliferating tumor cells.